1. Research progress on sodium-glucose cotransporter 2 inhibitors for in-stent restenosis after percutaneous coronary intervention.
- Author
-
ZHANG Qing, LI Tudi, CHEN Rong, and ZENG Zhihuan
- Subjects
- *
SODIUM-glucose cotransporter 2 inhibitors , *SODIUM-glucose cotransporters , *PERCUTANEOUS coronary intervention , *ORAL medication , *CORONARY disease , *DRUG-eluting stents , *CARDIAC patients , *HYPOGLYCEMIC agents - Abstract
In-stent restenosis is one of the main causes of postoperative complications after percutaneous coronary intervention and a challenge in the field of intervention.Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral hypoglycemic agents used in the treatment of diabetes in recent years. In addition to lowering bloodglucose, they also have the effects of lowering blood pressure, improving blood lipids, and reducing weight, thereby protecting cardiovascular function. Recent studies have shown that SGLT2i can reduced the occurrence of in-stent restenosis and significantly improved the prognosis of patients with coronary heart disease receiving interventional therapy.This article reviews the clinical studies and mechanisms of SGLT2i in the prevention of restenosis after percutaneous coronary intervention, providing new ideas for improving the clinical prognosis of patients with coronary heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF